Skip header and navigation

Refine By

167 records – page 1 of 17.

A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.

https://arctichealth.org/en/permalink/ahliterature162371
Source
Biol Blood Marrow Transplant. 2007 Aug;13(8):956-64
Publication Type
Article
Date
Aug-2007
Author
Mitchell Sabloff
Harold L Atkins
Isabelle Bence-Bruckler
Christopher Bredeson
Dean Fergusson
Paul Genest
Harry Hopkins
Brian Hutton
Sheryl Mcdiarmid
Lothar B Huebsch
Author Affiliation
The Ottawa Hospital Blood and Marrow Transplant Program, University of Ottawa, Ottawa, Ontario, Canada. msabloff@ottawahospital.on.ca
Source
Biol Blood Marrow Transplant. 2007 Aug;13(8):956-64
Date
Aug-2007
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Disease-Free Survival
Female
Hematopoietic Stem Cell Transplantation - adverse effects - methods
Humans
Longitudinal Studies
Lymphoma, Follicular - therapy
Male
Middle Aged
Neoplasm Recurrence, Local - therapy
Ontario
Retrospective Studies
Salvage Therapy - methods
Transplantation, Autologous - methods
Abstract
Autologous stem cell transplant (ASCT) has been shown to be an effective treatment for follicular lymphoma (FL). We explored our experience in ASCT for FL among all patients treated over a 15-year period from diagnosis through their entire treatment history including relapse post ASCT. All patients who underwent an unpurged ASCT for relapsed, advanced FL between June 1990 and December 2000 were analyzed. After salvage therapy they received melphalan/etoposide/total body irradiation, BCNU, etoposide, cytarabine, melphalan (BEAM), or cyclophosphamide BCNU etoposide (CBV) as conditioning for the ASCT. One hundred thirty-eight patients with a median age of 48 years and a median follow-up of 7.6 years were analyzed. The majority were of the subtype grade 1, nontransformed (FL-NT), having had 1 prior chemotherapy. The progression-free (PFS) and overall survival (OS) of the FL-NT at 10 years were 46% and 57%, respectively, and at 5 years for the transformed (FL-T) were 25% and 56%, respectively, of which only the PFS was significantly different (P=.007). The median OS from diagnosis was 16 years for the FL-NT. ASCT positively altered the trend of shorter remissions with subsequent chemotherapies, and there was no difference in OS between those who had 1, 2, or >2 chemotherapies prior to ASCT. Salvage therapy for relapse post ASCT was effective (OS>1 year) in a third of patients. Unpurged ASCT is an effective tool in the treatment of relapsed, aggressive FL-NT and FL-T, is superior to retreatment with standard chemotherapy, is effective at various stages of treatment, is likely to have a beneficial influence on the natural history of this disease, and the disease is amenable to salvage therapy post-ASCT relapse.
PubMed ID
17640600 View in PubMed
Less detail

86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children.

https://arctichealth.org/en/permalink/ahliterature282764
Source
J Assist Reprod Genet. 2017 Mar;34(3):325-336
Publication Type
Article
Date
Mar-2017
Author
Annette Klüver Jensen
Kirsten Tryde Macklon
Jens Fedder
Erik Ernst
Peter Humaidan
Claus Yding Andersen
Source
J Assist Reprod Genet. 2017 Mar;34(3):325-336
Date
Mar-2017
Language
English
Publication Type
Article
Keywords
Cryopreservation
Denmark
Female
Fertility Preservation
Fertilization in Vitro - methods
Humans
Infant, Newborn
Ovary - transplantation
Pregnancy
Pregnancy outcome
Premature Birth
Primary Ovarian Insufficiency - physiopathology
Transplantation, Autologous
Abstract
This study aims to make an account of the children born following transplantation of frozen-thawed ovarian tissue worldwide with specific focus on the perinatal outcome of the children. Furthermore, perinatal outcome of seven deliveries (nine children) from Denmark is reported.
PubMed was searched for papers of deliveries resulting from ovarian tissue cryopreservation (OTC). Seven women underwent OTC prior to chemotherapy. Four of these women still had low ovarian function and had tried to conceive. They therefore had tissue autotransplanted to augment their fertility. The other three women had developed premature ovarian insufficiency (POI) after the end of treatment.
Worldwide, approximately 95 children have been born or will be born in the near future from OTC, including these 9 new children. Information on the perinatal outcome was found on 40 children. The mean gestational age was 39 weeks and the mean birth weight was 3168 g of the singleton pregnancies, which is within internationally recognized normal standards. Furthermore, half the singletons resulted from natural conception and all twins resulted from in vitro fertilization treatment. All seven Danish women became pregnant within 1-3 years after transplantation. They gave birth to nine healthy children.
The data is reassuring and further suggests that cryopreservation of ovarian tissue is becoming an established fertility preservation method. The seven Danish women reported in this study were all in their early thirties when OTC was performed. Most other reported cases were in the women's twenties. This suggests that the follicular pool in the thirties is large enough and sufficient to sustain fertility.
Notes
Erratum In: J Assist Reprod Genet. 2017 Mar;34(3):33728120130
Cites: Acta Obstet Gynecol Scand. 2015 Sep;94(9):937-4126095872
Cites: Reprod Biomed Online. 2011 Feb;22(2):162-7121239230
Cites: Hum Reprod. 2016 Sep;31(9):2031-4127378768
Cites: Fertil Steril. 2012 Sep;98(3):720-522698640
Cites: Hum Reprod. 2010 May;25(5):1280-120172869
Cites: Fertil Steril. 2016 Aug;106(2):467-7427181924
Cites: Hum Reprod. 2003 Dec;18(12):2654-914645187
Cites: Lancet. 2004 Oct 16-22;364(9443):1405-1015488215
Cites: Hum Reprod. 2014 Jan;29(1):97-10624135076
Cites: Hum Reprod. 2009 Nov;24(11):2778-8719671623
Cites: Reprod Biomed Online. 2012 Aug;25(2):128-3222687323
Cites: Hum Reprod. 2011 May;26(5):1097-10321421665
Cites: Hum Reprod. 2015 Mar;30(3):608-1525567618
Cites: Hum Reprod. 2015 Sep;30(9):2107-926062556
Cites: Lancet. 2015 May 16;385(9981):1947-826090642
Cites: Am J Obstet Gynecol. 2016 Jan;214(1):94.e1-926601616
Cites: Fertil Steril. 2012 Feb;97(2):387-9022177311
Cites: Acta Obstet Gynecol Scand. 2016 Sep;95(9):1015-2627258933
Cites: J Ovarian Res. 2013 May 07;6(1):3323647552
Cites: Theriogenology. 2007 Jan 1;67(1):73-8017055564
Cites: Hum Reprod. 2015 Dec;30(12):2838-4526443605
Cites: J Assist Reprod Genet. 2016 Dec;33(12 ):1615-162027639996
Cites: Hum Reprod. 2014 Aug;29(8):182824871346
Cites: N Engl J Med. 2005 Jul 21;353(3):318-2115983020
Cites: Hum Reprod. 2010 Jun;25(6):1590-120395218
Cites: Reprod Biomed Online. 2015 Jun;30(6):643-5025892498
Cites: Fertil Steril. 2011 Apr;95(5):1787.e1-421145049
Cites: Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17474-924082083
Cites: Hum Reprod. 2008 Oct;23(10):2266-7218603535
Cites: Fertil Steril. 2010 Jan;93(1):268.e11-319880105
Cites: J Assist Reprod Genet. 2014 Nov;31(11):1557-6425212530
Cites: Fertil Steril. 2010 May 1;93(7):2413.e15-920117783
Cites: Hum Reprod. 2008 Nov;23(11):2475-8318635528
Cites: J Assist Reprod Genet. 2015 Aug;32(8):1167-7026210678
Cites: Ann Med. 2011;43(6):437-5021226660
Cites: Reproduction. 2013 Oct 21;146(6):R205-1523929903
Cites: Fertil Steril. 2013 Jan;99(1):227-3023102860
Cites: Oncologist. 2007 Dec;12(12):1437-4218165621
Cites: Fertil Steril. 2015 Feb;103(2):462-825487750
Cites: Fertil Steril. 2012 Jun;97(6):1394-8.e122425199
Cites: Hum Reprod. 2013 Nov;28(11):2996-924014608
Cites: Acta Obstet Gynecol Scand. 2015 Mar;94(3):324-825545009
PubMed ID
28028773 View in PubMed
Less detail

ACL reconstruction: patellar tendon versus hamstring grafts--economical aspects.

https://arctichealth.org/en/permalink/ahliterature170011
Source
Knee Surg Sports Traumatol Arthrosc. 2006 Jun;14(6):536-41
Publication Type
Article
Date
Jun-2006
Author
Magnus Forssblad
Anders Valentin
Björn Engström
Suzanne Werner
Author Affiliation
Capio Artro Clinic, Stockholm Sport Trauma Research Center, Sophiahemmet, 114 27, Stockholm, Sweden. magnus.forssblad@capio.se
Source
Knee Surg Sports Traumatol Arthrosc. 2006 Jun;14(6):536-41
Date
Jun-2006
Language
English
Publication Type
Article
Keywords
Adult
Anterior Cruciate Ligament - injuries - surgery
Bone Screws
Bone-Patellar Tendon-Bone Grafting - economics
Costs and Cost Analysis
Female
Humans
Male
Prospective Studies
Sweden
Tendons - transplantation
Transplantation, Autologous - economics
Abstract
The aim of the present investigation was to compare the costs for the use of patellar tendon versus hamstring tendons as grafts for anterior cruciate ligament (ACL) reconstruction including the different fixation methods. The background is that during recent years there has been a dramatic shift from patellar tendon to hamstring tendons in ACL reconstructions in Sweden. All our patients with ACL reconstructions performed during 1 year (2004) were included. Knee joints numbering 440 in 439 patients were primary ACL reconstructions. A hamstring graft was used in 345 knee joints (78.4%) and a patellar tendon graft in 95 (21.6%) of the patients (Table 2). On average 34 (SD 12.9; range 14-63) ACL reconstructions per surgeon were performed by a total of 14 surgeons. The average cost for patellar tendon procedure was 197 euros compared to 436 euros for the hamstring procedure. Mean time for surgery in primary reconstructions was 11.5 min shorter (P
PubMed ID
16570193 View in PubMed
Less detail

Adverse events during treatment of critical limb ischemia with autologous peripheral blood mononuclear cell implant.

https://arctichealth.org/en/permalink/ahliterature127035
Source
Int Angiol. 2012 Feb;31(1):77-84
Publication Type
Article
Date
Feb-2012
Author
T B Jonsson
T. Larzon
B. Arfvidsson
U. Tidefelt
C G Axelsson
M. Jurstrand
L. Norgren
Author Affiliation
Department of Surgery, University Hospital, Örebro, Sweden. thomas.jonsson@surgsci.uu.se
Source
Int Angiol. 2012 Feb;31(1):77-84
Date
Feb-2012
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Amputation
Angiography, Digital Subtraction
Ankle Brachial Index
Critical Illness
Cytokines - blood
Drug Administration Schedule
Female
Granulocyte Colony-Stimulating Factor - administration & dosage
Heart Failure - etiology - mortality
Hematopoietic Stem Cell Mobilization
Humans
Intercellular Signaling Peptides and Proteins - blood
Ischemia - blood - complications - diagnosis - mortality - physiopathology - surgery
Limb Salvage
Lower Extremity - blood supply
Male
Mesenteric Vascular Occlusion - etiology - mortality
Middle Aged
Myocardial Infarction - etiology
Pain - etiology - prevention & control
Pain Measurement
Peripheral Blood Stem Cell Transplantation - adverse effects - mortality
Pilot Projects
Predictive value of tests
Recombinant Proteins - administration & dosage
Reoperation
Risk assessment
Risk factors
Sweden
Thrombosis - etiology - mortality
Time Factors
Transplantation, Autologous
Treatment Outcome
Wound Healing
Abstract
Trials have reported clinical improvement and reduced need for amputation in critical limb ischemia (CLI) patients receiving therapeutic angiogenesis with stem cells. Our objective was to test peripheral stem cell therapy efficacy and safety to gain experiences for further work.
We included nine CLI patients (mean age 76.7 ±9.7). Stem cells were mobilized to the peripheral blood by administration of G-CSF (Filgrastim) for 4 days, and were collected on day five, when 30 mL of a stem cell suspension was injected into 40 points of the limb. The clinical efficacy was evaluated by assessing pain relief, wound healing and changes in ankle-brachial pressure index (ABI). Local metabolic and inflammatory changes were measured with microdialysis, growth factors and cytokine level determination. Patients were followed for 24 weeks.
Four patients experienced some degree of improvement with pain relief and/or improved wound healing and ABI increase. One patient was lost to follow up due to chronic psychiatric illness; one was amputated after two weeks. Two patients had a myocardial infarction (MI), one died. One patient died from a massive mesenteric thrombosis after two weeks and one died from heart failure at week 11. Improved patients showed variable effects in cytokine-, growth factor- and local metabolic response.
Even with some improvement in four patients, severe complications in four out of nine patients, and two in relation to the bone marrow stimulation, made us terminate the study prematurely. We conclude that with the increased risk and the reduced potential of the treatment, peripheral blood stem cell treatment in the older age group is less appropriate. Metabolic and inflammatory response may be of value to gain insight into mechanisms and possibly to evaluate effects of therapeutic angiogenesis.
PubMed ID
22330628 View in PubMed
Less detail

Allogeneic bone marrow transplantation versus chemotherapy in children with acute leukemia in Sweden.

https://arctichealth.org/en/permalink/ahliterature25653
Source
Pediatr Hematol Oncol. 1989;6(2):137-44
Publication Type
Article
Date
1989
Author
O. Ringdén
P. Bolme
B. Lönnqvist
G. Gustafsson
A. Kreuger
Author Affiliation
Department of Clinical Immunology, Huddinge Hospital, Sweden.
Source
Pediatr Hematol Oncol. 1989;6(2):137-44
Date
1989
Language
English
Publication Type
Article
Keywords
Actuarial Analysis
Acute Disease
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone Marrow Transplantation
Combined Modality Therapy
Comparative Study
Evaluation Studies
Humans
Leukemia, Lymphocytic, Acute - drug therapy - mortality - surgery
Leukemia, Myeloid - drug therapy - mortality - surgery
Remission Induction
Research Support, Non-U.S. Gov't
Survival Rate
Sweden - epidemiology
Transplantation, Autologous
Abstract
All children in Sweden who underwent bone marrow transplantation (BMT) with an HLA-identical sibling during a 5-year period were compared to those who were treated with chemotherapy and survived at least 3 months after remission. All patients were observed for more than 2 years after diagnosis or relapse. All 11 children with acute myeloid leukemia in first remission who underwent BMT survived compared to only 1 of 15 treated with chemotherapy (p less than 0.001). In children with acute lymphoblastic leukemia (ALL), those relapsing while on chemotherapy and treated with BMT in second to fourth remission (n = 16) had a 5-year survival of 43% compared to 16% for those treated with chemotherapy (n = 53, p less than 0.05). In children with ALL relapsing after cessation of therapy, 4-year survival was 33% for BMT (n = 6) and 55% for chemotherapy (n = 15), p = 0.05).
PubMed ID
2702067 View in PubMed
Less detail

Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder.

https://arctichealth.org/en/permalink/ahliterature139993
Source
Bone Marrow Transplant. 2011 Jun;46(6):870-5
Publication Type
Article
Date
Jun-2011
Author
J E Johansson
M. Remberger
V Lj Lazarevic
H. Hallböök
A. Wahlin
E. Kimby
G. Juliusson
H. Omar
H. Hägglund
Author Affiliation
Department of Hematology and Coagulation, Sahlgrenska University Hospital, Göteborg, Sweden. jan-erik.j.johansson@vgregion.se
Source
Bone Marrow Transplant. 2011 Jun;46(6):870-5
Date
Jun-2011
Language
English
Publication Type
Article
Keywords
Adult
Data Collection
Female
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation - adverse effects - methods
Hodgkin Disease - complications - therapy
Humans
Incidence
Lymphoproliferative Disorders - epidemiology - etiology
Male
Middle Aged
Survival Analysis
Sweden - epidemiology
Transplantation Conditioning - adverse effects - methods
Transplantation, Autologous
Transplantation, Homologous
Treatment Outcome
Young Adult
Abstract
Allogeneic transplantation after reduced intensity conditioning (allo-RIC) is a treatment option for patients with Hodgkin's lymphoma (HL) relapsing after autologous transplantation. In all, 23 adult patients with HL underwent allo-RIC in Sweden between 2000 and 2007. The median number of previous treatment lines was five and 20 patients (87%) were previously autografted. TRM at 100 days and at 1 year was 13 and 22% respectively. Acute GVHD grades II-IV developed in 7 out of 23 patients (30%) and chronic GVHD in 10 out of 20 patients at risk (50%). The OS and EFS at three years was 59 and 27%, respectively. Four patients (17%) developed post transplant lymphoproliferative disease (PTLD) after a median time of 55 days (range 38-95); two of these patients later died. The study confirmed that allo-RIC is feasible, but associated with a substantial relapse rate: only 20% of the patients were still alive 7 years after the transplant. A finding of high incidence of PTLD needs to be confirmed in a larger trial that includes patients with non-HL and CLL.
PubMed ID
20956959 View in PubMed
Less detail

Autografting in chronic myeloid leukemia with cultured marrow: update of the Vancouver Study.

https://arctichealth.org/en/permalink/ahliterature220253
Source
Stem Cells. 1993 Oct;11 Suppl 3:64-6
Publication Type
Article
Date
Oct-1993
Author
M J Barnett
C J Eaves
G L Phillips
D E Hogge
H G Klingemann
P M Lansdorp
S H Nantel
D E Reece
J D Shepherd
H J Sutherland
Author Affiliation
Leukemia/Bone Marrow Transplantation Program of British Columbia, Vancouver General Hospital, Canada.
Source
Stem Cells. 1993 Oct;11 Suppl 3:64-6
Date
Oct-1993
Language
English
Publication Type
Article
Keywords
Adult
Bone Marrow Transplantation - methods
British Columbia - epidemiology
Combined Modality Therapy
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy - epidemiology - therapy
Middle Aged
Transplantation, Autologous
Tumor Cells, Cultured
Abstract
When chronic myeloid leukemia (CML) marrow is set up in long-term culture (LTC), Philadelphia chromosome (Ph)-positive (Ph+) cells typically decline and Ph-negative (Ph-) hematopoietic cells often become detectable. In 1987, we initiated a study to evaluate the feasibility of using 10-day cultured marrow autografts to allow intensive treatment of CML. Patients were selected on the basis of a previous assessment of the frequencies of normal and leukemic LTC-initiating cells (LTC-IC) remaining in their marrow after 10 days of LTC. Of the 87 patients evaluated, 36 (41%) were considered eligible, and 22 (15 in first chronic phase [CP], Group 1; and 7 with more advanced disease, Group 2) were autografted with 10-day cultured marrow after intensive therapy. Satisfactory hematological recovery occurred in 16 patients, and of these, only Ph- cells were detected in 13 (nine in Group 1), with 76-94% Ph- cells in the other three (two in Group 1). Ph+ cells reappeared between 4 and 36 months post-autograft in all but one of the 13 patients in whom complete (morphological and cytogenetic) remission had been achieved; the remaining patient died in remission. Nine of these twelve patients were then treated with alpha-interferon (IFN-alpha) 1-3 x 10(6) units/m2, 3-7 days/week; four returned to complete remission, three developed increasing numbers of Ph+ cells, and two are still too early to evaluate. Fifteen patients (12 in Group 1) remain alive and well, nine in hematological remission (eight in Group 1), 9 to 64 months (median 28) post-autograft.(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed ID
7905324 View in PubMed
Less detail

Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience.

https://arctichealth.org/en/permalink/ahliterature17073
Source
Bone Marrow Transplant. 2005 Jun;35(12):1141-8
Publication Type
Article
Date
Jun-2005
Author
H. Hallböök
H. Hägglund
D. Stockelberg
P-G Nilsson
K. Karlsson
M. Björkholm
M. Linderholm
A. Wahlin
O. Linder
B. Smedmyr
Author Affiliation
Department of Haematology, University Hospital, Uppsala, Sweden. helene.hallbook@medsci.uu.se
Source
Bone Marrow Transplant. 2005 Jun;35(12):1141-8
Date
Jun-2005
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Comparative Study
Disease-Free Survival
Female
Graft vs Host Disease
Graft vs Leukemia Effect
Hematopoietic Stem Cell Transplantation - methods
Humans
Leukemia, Lymphocytic, Acute, L2 - therapy
Male
Middle Aged
Philadelphia Chromosome
Probability
Recurrence
Retrospective Studies
Sweden
Tissue Donors
Transplantation, Autologous
Transplantation, Homologous
Abstract
Adult patients with acute lymphoblastic leukaemia (ALL) have been treated according to national protocols in Sweden since 1986. Stem cell transplantation (SCT) has been recommended in first remission for patients with risk factors for relapse, and for standard risk patients only after relapse. In this retrospective study, the results of autologous and allogeneic SCT in these populations were evaluated. In total, 187 patients with a median age of 34 years (17-66 years) underwent SCT. The 5-year disease-free survival (DFS), for all patients, was 26% (Confidence intervals (CI) 20-32%). The 5-year DFS was higher for patients transplanted in first remission 32% (CI 24-40%) compared to 14% (CI 5-23%; P
PubMed ID
15834433 View in PubMed
Less detail

[Autologous bone marrow transplantation in children]

https://arctichealth.org/en/permalink/ahliterature24036
Source
Ugeskr Laeger. 1993 May 17;155(20):1531-5
Publication Type
Article
Date
May-17-1993
Author
N. Clausen
H. Schrøder
Author Affiliation
Arhus Kommunehospital, paediatrisk afdeling.
Source
Ugeskr Laeger. 1993 May 17;155(20):1531-5
Date
May-17-1993
Language
Danish
Publication Type
Article
Keywords
Bone Marrow Transplantation - methods - statistics & numerical data - utilization
Child
Denmark
English Abstract
Female
Humans
Male
Transplantation, Autologous
Abstract
Autologous bone marrow transplantation is used for children with cancers which are only partially responsive to bone marrow toxic doses of cancer chemotherapy and irradiation. The use of megatherapy and autologous bone marrow transplantation instead of conventional doses for children has yielded substantial benefits in B-cell lymphoma, relapse of leukaemia, disseminated neuroblastoma and germ cell tumors. In the case of Wilms' tumor, rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma with a partial initial response or a relapse, autologous bone marrow transplantation has been used to a limited extent. Based on the best results from conventional therapy and autologous bone marrow transplantation, respectively, the present need for autologous bone marrow transplantation in Denmark is estimated to be 24 transplantations a year.
PubMed ID
8316984 View in PubMed
Less detail

167 records – page 1 of 17.